FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
PRINCETON, N.J., Jan. 15, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women’s health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, announced today that Katie MacFarlane, Chief Commercial Officer, will present at Noble Financial Capital Markets’ Twelfth Annual Equity Conference on Monday, January 18, 2016 at 11:30 AM ET.
About Agile Therapeutics, Inc.
Agile Therapeutics is a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products. Our product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adherence and patient acceptability.
Contact Mary Coleman 609-683-1880
